In a June 10 story about diabetes treatment research, The Associated Press reported erroneously that LY2605541 is a short-acting insulin. It is a long-acting insulin.
Also, Johnson & Johnson applied for U.S. approval to sell its experimental diabetes pill canagliflozin on May 31, not May 29.
WH Totally Supports What Planned Parenthood Is Doing, Notes Its 'High Ethical Standard' | Leah Barkoukis
Video: Visitors Leaving National Archives Mostly Clueless About Their First Amendment Rights | Matt Vespa